JP2010540570A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540570A5
JP2010540570A5 JP2010527303A JP2010527303A JP2010540570A5 JP 2010540570 A5 JP2010540570 A5 JP 2010540570A5 JP 2010527303 A JP2010527303 A JP 2010527303A JP 2010527303 A JP2010527303 A JP 2010527303A JP 2010540570 A5 JP2010540570 A5 JP 2010540570A5
Authority
JP
Japan
Prior art keywords
composition
antigen
composition according
amphiphilic compound
hydrophobic carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010527303A
Other languages
Japanese (ja)
Other versions
JP5591705B2 (en
JP2010540570A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/001747 external-priority patent/WO2009043165A1/en
Publication of JP2010540570A publication Critical patent/JP2010540570A/en
Publication of JP2010540570A5 publication Critical patent/JP2010540570A5/ja
Application granted granted Critical
Publication of JP5591705B2 publication Critical patent/JP5591705B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (21)

抗原、
両親媒性化合物、及び
疎水性担体
を含有する、実質的に水を含まない組成物。 antigen,
A composition substantially free of water, comprising an amphiphilic compound and a hydrophobic carrier. 前記組成物の総重量に基づき、１０重量％未満の水を含む、請求項１に記載の組成物。   The composition of claim 1 comprising less than 10% water by weight based on the total weight of the composition. 抗原の２０重量％未満が水に懸濁している、請求項１又は２に記載の組成物。   The composition according to claim 1 or 2, wherein less than 20% by weight of the antigen is suspended in water. 前記疎水性担体が乳化剤を含む、請求項１から３のいずれか一項に記載の組成物。   The composition according to any one of claims 1 to 3, wherein the hydrophobic carrier comprises an emulsifier. 前記両親媒性化合物がリン脂質を含む、請求項１から４のいずれか一項に記載の組成物。   The composition according to any one of claims 1 to 4, wherein the amphiphilic compound comprises a phospholipid. 前記両親媒性化合物がレシチンである、請求項１から４のいずれか一項に記載の組成物。   The composition according to any one of claims 1 to 4, wherein the amphiphilic compound is lecithin. 前記疎水性担体が油又は油の混合物を含む、請求項１から６のいずれか一項に記載の組成物。   7. A composition according to any one of the preceding claims, wherein the hydrophobic carrier comprises an oil or a mixture of oils. 前記乳化剤が、Ｓｐａｎ８０、オレイン酸マンニド又はそれらの混合物を含む、請求項４に記載の組成物。   The composition of claim 4, wherein the emulsifier comprises Span 80, oleic mannide or mixtures thereof. 前記抗原が、ポリペプチド、ポリペプチドをコードするポリヌクレオチド、ペプチド、生菌、死菌、生ウイルス、弱毒化ウイルス、不活性化細菌、又はそれらの部分を含む、請求項１から８のいずれか一項に記載の組成物。   The antigen according to any one of claims 1 to 8, wherein the antigen comprises a polypeptide, a polynucleotide encoding the polypeptide, a peptide, a live bacterium, a dead bacterium, a live virus, an attenuated virus, an inactivated bacterium, or a part thereof. The composition according to one item. アジュバントをさらに含む、請求項１から９のいずれか一項に記載の組成物。   The composition according to any one of claims 1 to 9, further comprising an adjuvant. 組成物１ｍｌにつき両親媒性化合物約０．１〜約２５０ｍｇを含む、請求項１から１０のいずれか一項に記載の組成物。   11. A composition according to any one of the preceding claims comprising from about 0.1 to about 250 mg of amphiphilic compound per ml of composition. 疎水性担体が約５重量％〜約１５重量の％乳化剤を含む、請求項４に記載の組成物。   The composition of claim 4, wherein the hydrophobic carrier comprises from about 5% to about 15% by weight of emulsifier. 前記抗原と前記両親媒性化合物とが第１容器中で乾燥混合物として提供され、前記疎水性担体と乳化剤とが第２容器中で提供される、請求項１から１２のいずれか一項に記載の組成物。   13. The antigen and the amphiphilic compound are provided as a dry mixture in a first container and the hydrophobic carrier and emulsifier are provided in a second container as claimed in any one of claims 1-12. Composition. （ａ）抗原と両親媒性化合物とを組み合わせて乾燥混合物を形成すること、及び
（ｂ）前記混合物を疎水性担体に懸濁すること
を含む、請求項１から１３のいずれか一項に記載の組成物を作製するための工程。 14. The method of any one of claims 1 to 13, comprising: (a) combining an antigen and an amphiphilic compound to form a dry mixture; and (b) suspending the mixture in a hydrophobic carrier. A process for producing the composition. アジュバントを組成物に添加することをさらに含む、請求項１４に記載の工程。   15. The process of claim 14, further comprising adding an adjuvant to the composition. 前記疎水性担体が乳化剤を含む、請求項１４又は１５に記載の工程。   The process according to claim 14 or 15, wherein the hydrophobic carrier comprises an emulsifier. 前記組合せ段階が、
前記抗原を可溶化すること、
前記両親媒性化合物を可溶化すること、
前記可溶化抗原と前記可溶化両親媒性化合物とを組み合わせて混合物を形成すること、
及び
前記混合物を乾燥すること
を含む、請求項１４から１６のいずれか一項に記載の工程。 The combination step is
Solubilizing the antigen,
Solubilizing the amphiphilic compound,
Combining the solubilized antigen and the solubilized amphiphilic compound to form a mixture;
The process according to any one of claims 14 to 16, comprising drying the mixture. 前記組合せ段階が、前記抗原を前記両親媒性化合物と共に乾式粉砕することを含む、請求項１４から１６のいずれか一項に記載の工程。   The process according to any one of claims 14 to 16, wherein the combining step comprises dry milling the antigen with the amphiphilic compound. 対象に投与されることを特徴とする、請求項１から１３のいずれか一項に記載の組成物。 14. A composition according to any one of claims 1 to 13, characterized in that it is administered to a subject. 対象において抗体応答又は細胞媒介性免疫応答を誘導するための、対象に投与されることを特徴とする、請求項１から１３のいずれか一項に記載の組成物。 14. Composition according to any one of the preceding claims, characterized in that it is administered to a subject for inducing an antibody response or a cell-mediated immune response in the subject . 前記組成物が、経口的、経鼻的、経直腸的又は非経口的に投与されるものである、請求項１９又は２０に記載の組成物。 Wherein the composition, orally, nasally, is to be administered rectally or parenterally, the composition according to claim 19 or 20.
JP2010527303A 2007-10-03 2008-10-02 Composition comprising antigen, amphiphilic compound and hydrophobic carrier, and use thereof Active JP5591705B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97719707P 2007-10-03 2007-10-03
US60/977,197 2007-10-03
PCT/CA2008/001747 WO2009043165A1 (en) 2007-10-03 2008-10-02 Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof

Publications (3)

Publication Number Publication Date
JP2010540570A JP2010540570A (en) 2010-12-24
JP2010540570A5 true JP2010540570A5 (en) 2011-11-10
JP5591705B2 JP5591705B2 (en) 2014-09-17

Family

ID=40525804

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527303A Active JP5591705B2 (en) 2007-10-03 2008-10-02 Composition comprising antigen, amphiphilic compound and hydrophobic carrier, and use thereof

Country Status (7)

Country Link
EP (1) EP2195022A4 (en)
JP (1) JP5591705B2 (en)
CN (1) CN101815529B (en)
AU (1) AU2008307042B2 (en)
BR (1) BRPI0817484B1 (en)
CA (1) CA2700828C (en)
WO (1) WO2009043165A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039628A1 (en) 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
JP5715051B2 (en) 2008-06-05 2015-05-07 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Composition comprising carrier comprising liposome, antigen, polynucleotide and continuous phase of hydrophobic substance
JP6240077B2 (en) 2011-10-06 2017-11-29 イムノバクシーン・テクノロジーズ・インコーポレイテッドＩｍｍｕｎｏｖａｃｃｉｎｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｉｎｃ． Liposome composition comprising an adjuvant that activates or increases its activity and its use
US10022441B2 (en) 2013-03-27 2018-07-17 Immunovaccine Technologies, Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
CN107531736B (en) 2015-01-06 2022-04-15 免疫疫苗科技公司 Lipid A mimetics, methods of making and uses thereof
CN105044328A (en) * 2015-05-28 2015-11-11 首都医科大学附属北京佑安医院 Elispot pre-coated culture plate and preparation method thereof
AU2016355926A1 (en) * 2015-11-18 2018-05-31 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:C polynucleotide adjuvant and a lipid-based adjuvant
CN109328070A (en) * 2016-05-04 2019-02-12 免疫疫苗技术有限公司 Vaccine composition and its application method comprising amphipathic compound, neoantigen and hydrophobic carrier
EP3518963A4 (en) 2016-09-27 2020-06-10 ImmunoVaccine Technologies Inc. Methods of using low dose volume b-cell epitope compositions for inducing an antibody immune response in human subjects
AU2019239785A1 (en) * 2018-03-20 2020-10-08 Immunovaccine Technologies Inc. Methods and compositions for targeted delivery of active agents and immunomodulatory agents to lymph nodes
KR20230147135A (en) * 2021-02-16 2023-10-20 백시테크 노쓰 아메리카, 인크. Self-assembling nanoparticles based on amphiphilic peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950700083A (en) * 1992-03-03 1995-01-16 스즈키 다다시 ORAL VACCINE
US5736141A (en) * 1992-06-05 1998-04-07 Dalhousie University Method to prevent fertilization in mammals by administering a single dose of zona pellucida derived antigens, liposome and Freund's adjuvant
GB9422990D0 (en) * 1994-11-15 1995-01-04 Cortecs Ltd Immunogenic compositions
WO1998053799A2 (en) * 1997-05-28 1998-12-03 Jenner Biotherapies, Inc. Immunogenic compositions
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
AU2002214861B2 (en) * 2000-11-07 2006-09-28 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy

Similar Documents

Publication Publication Date Title
JP2010540570A5 (en)
Song et al. Engineering the deformability of albumin‐stabilized emulsions for lymph‐node vaccine delivery
Ghasparian et al. Engineered Synthetic Virus‐Like Particles and Their Use in Vaccine Delivery
EA200901161A1 (en) VACCINE AGAINST THE FLU IN THE FORM OF THE TYPE "OIL IN WATER" EMULSION
JP2009527572A5 (en)
RU2009144125A (en) VIROSOMES CONTAINING HEMAGGLUTININ, OBTAINED FROM INFLUENZA VIRUS, PRODUCED IN THE CELL LINE; COMPOSITIONS, PRODUCTION METHODS AND APPLICATION BASED ON THEM
Sundararajan et al. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine
JP2017165748A5 (en)
MX2018007860A (en) Recombinant zika vaccines.
ATE555808T1 (en) VACCINE COMPOSITION CONTAINING A SYNTHETIC ADJUVANT
WO2015043613A8 (en) Particles comprising a shell with rna
JP2007327074A5 (en)
JP2006232799A (en) COMPOSITION OF POLY-gamma-GLUTAMIC ACID-CONTAINING IMMUNOPOTENTIATING AGENT
JP2010500398A5 (en)
JP2014532620A5 (en)
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
JP2014502156A5 (en)
EA200901434A1 (en) THE LYOPHILISING ANTIGEN COMPOSITION
JP2013545448A5 (en)
RU2017101091A (en) COMPOSITIONS OF DOUBLE ADJUVANT VACCINES, OBTAINING AND APPLICATIONS
JP2013518052A5 (en)
Li et al. Co-stimulation with TLR7 agonist imiquimod and inactivated influenza virus particles promotes mouse B cell activation, differentiation, and accelerated antigen specific antibody production
Kianmehr et al. Influence of Brucella abortus lipopolysaccharide as an adjuvant on the immunogenicity of HPV-16 L1VLP vaccine in mice
RU2017124240A (en) METHOD FOR OBTAINING READY TO USE COMBINED VACCINE AGAINST PCV2 / M.hyo
JP2018500878A5 (en)